Eton Drug Patent Portfolio
Eton owns 4 orange book drugs protected by 9 US patents Given below is the list of Eton's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12214010 | Desmopressin Oral Compositions | 03 Apr, 2044 | Active |
| US12343372 | Desmopressin Oral Compositions | 03 Apr, 2044 | Active |
| US11904046 | 23 Feb, 2043 | Active | |
| US12133914 | Hydrocortisone Oral Liquid Formulations | 23 Feb, 2043 | Active |
| US9649280 | Composition comprising hydrocortisone | 12 May, 2034 | Active |
| US9675559 | Treatment of adrenal insufficiency | 10 Jan, 2033 | Active |
| US9717740 | Treatment of adrenal insufficiency | 19 Nov, 2032 | Active |
| US8338489 | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas | 16 Oct, 2028 | Active |
| US8987262 | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas | 16 Oct, 2028 | Active |
Latest Legal Activities on Eton's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Eton.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Feb, 2025 | US9717740 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Dec, 2024 | US9675559 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Nov, 2024 | US9649280 |
| Patent Issue Date Used in PTA Calculation | 05 Nov, 2024 | US12133914 |
| Mail Patent eGrant Notification | 05 Nov, 2024 | US12133914 |
| Recordation of Patent eGrant | 05 Nov, 2024 | US12133914 |
| Patent eGrant Notification | 05 Nov, 2024 | US12133914 |
| Email Notification | 05 Nov, 2024 | US12133914 |
| Recordation of Patent Grant Mailed | 05 Nov, 2024 | US12133914 |
| Email Notification | 16 Oct, 2024 | US12133914 |
| Issue Notification Mailed | 16 Oct, 2024 | US12133914 |
| Email Notification | 01 Oct, 2024 | US12133914 |
| Mail Response to 312 Amendment (PTO-271) | 01 Oct, 2024 | US12133914 |
| Dispatch to FDC | 30 Sep, 2024 | US12133914 |
| Application Is Considered Ready for Issue | 30 Sep, 2024 | US12133914 |
Eton Drug Patents' Oppositions Filed in EPO
Eton drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 09, 2012, by Infectopharm Arzneimittel Und Consilium Gmbh. This opposition was filed on patent number EP08838691A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP08838691A | Mar, 2012 | Infectopharm Arzneimittel und Consilium GmbH | Opposition rejected |
Eton's Family Patents
Eton Drug List
Given below is the complete list of Eton's drugs and the patents protecting them.
1. Alkindi Sprinkle
Alkindi Sprinkle is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9649280 | Composition comprising hydrocortisone |
12 May, 2034
(8 years from now)
| Active |
| US9675559 | Treatment of adrenal insufficiency |
10 Jan, 2033
(6 years from now)
| Active |
| US9717740 | Treatment of adrenal insufficiency |
19 Nov, 2032
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Alkindi Sprinkle's drug page
2. Desmoda
Desmoda is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12214010 | Desmopressin Oral Compositions |
03 Apr, 2044
(17 years from now)
| Active |
| US12343372 | Desmopressin Oral Compositions |
03 Apr, 2044
(17 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Desmoda's drug page
3. Hemangeol
Hemangeol is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8338489 | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
16 Oct, 2028
(2 years from now)
| Active |
| US8987262 | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
16 Oct, 2028
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Hemangeol's drug page
4. Khindivi
Khindivi is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11904046 |
23 Feb, 2043
(16 years from now)
| Active | |
| US12133914 | Hydrocortisone Oral Liquid Formulations |
23 Feb, 2043
(16 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Khindivi's drug page